Is there a place for LDL-apheresis in the management of raised cholesterol?

Future Lipidology

Volumn 3, Issue 1, 2008, Pages 1-3

  Pottle, Alison ^a   Barbir, Mahmoud ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYACRYLIC ACID; SEPHAROSE; VERY LOW DENSITY LIPOPROTEIN;

ANGINA PECTORIS; APHERESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; EPIDEMIC; FAMILIAL HYPERCHOLESTEROLEMIA; FILTRATION; FLUSHING; HEADACHE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTENSION; IMMUNOADSORPTION; INCIDENCE; MORBIDITY; MORTALITY; NAUSEA; PATIENT SAFETY; PLASMAPHERESIS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 40749115900     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.1.1     Document Type: Editorial

References (4)

1. Thompson GR, Lowenthal R, Myant R: Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1, 1208-1211 (1975).
2. Stoffel W, Borberg H, Greve V: Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 2, 1005-1007 (1981).
3. Bambauer R, Schiel R, Latza R: Low-density lipoprotein apheresis: an overview. Ther. Apher. Dial. 7, 383-390 (2003).
4. Archontakis S, Pottle A, Hakim N, lisley C, Barbir M: LDL-apheresis: indications and clinical experience in a tertiary cardiac centre. Int. J. Clin. Pract. 61, 1834-1842 (2007).